Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13.

$80M series C for Versant-grown Pipeline
Neuroregeneration company Pipeline Therapeutics Inc. raised $80 million in a series C round, with participation by new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital and Red Tree Venture Capital. All the company’s existing shareholders, including founding investor Versant Ventures, Sectoral Asset Management and Cleva Pharma also joined...